It was subsequently confirmed as having imprecise diagnostic criteria based on collective descriptions lacking in agreement.However, in an experiment with a small sample size, five patients with a diagnosis of simple deteriorative disorder (DSM-IV) were found to have grey matter deficits, atrophy and reduced cerebral perfusion in the frontal areas. Whitwell et al. found justification to retain the classification on the basis of fulfillment of "dimensional" considerations of classification, as opposed to criticisms resulting from disagreement in considerations of classification using orientation from other categories. References


== External links ==
Gene therapy approaches for treating FVII deficiency are very promising ()

Medical uses
Recombinant factor VIIa, marketed under the trade names AryoSeven and NovoSeven, is used for people with hemophilia (with Factor VIII or IX deficiency) who have developed antibodies against replacement coagulation factor. It has also been used in the setting of uncontrollable hemorrhage, but its role in this setting is controversial with insufficient evidence to support its use outside of clinical trials. The first report of its use in hemorrhage was in an Israeli soldier with uncontrollable bleeding in 1999. Risks of its use include an increase in arterial thrombosis. However, animal studies have not shown complications as seen in humans, in fact same of the studies show a better prognosis. In the military settings it is used as an off label intervention in complications related to disseminated intravascular coagulation related haemorrhage caused by penetrating trauma.Recombinant human factor VII while initially looking promising in intracerebral hemorrhage failed to show benefit following further study and this is no longer recommended. Interactions
Factor VII has been shown to interact with tissue factor and protein kinase C.

References
Further reading
External links
Official website
The MEROPS online database for peptidases and their inhibitors: S01.215
CHES - Comprehensive Health Education Services LLC - Factor VII treatment and awareness [1]